Jounce Therapeutics, Inc. (JNCE) Social Stream
Featured Post From StockTwits About JNCE
$JNCE Pipeline Update:BioOption, published August 5, 2021
Monotherapy dose escalation portion of the Phase 1 trial of JTX-8064 is complete. The monotherapy dose ranging from 50 mg to 1200 mg. To date, JTX-8064 has been well-tolerated with no dose limiting toxicities. For the next stages of INNATE Jounce announces today the selection of its target dose of 700 mg.